Sign up to save your podcasts
Or
Share FDA Priority Review for Post-Neoadjuvant T-DXd in HER2+ Early BC
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
FDA Priority Review for Post-Neoadjuvant T-DXd in HER2+ Early BC
The FDA granted Priority Review to trastuzumab deruxtecan for high-risk HER2-positive early breast cancer with residual disease, signaling a potential new standard to reduce recurrence risk.
View all episodes
By TheBrief.HealthThe FDA granted Priority Review to trastuzumab deruxtecan for high-risk HER2-positive early breast cancer with residual disease, signaling a potential new standard to reduce recurrence risk.